Colorado plans to limit insurance coverage for weight-loss drugs like Wegovy and Ozempic for thousands of state employees.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo Nordisk (NVO) stock jumped 12% in pre-market trading Friday after it released promising results of an early-stage weight ...

One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

Professor Tim Spector has issued an urgent warning to people who may wish to take Ozempic "without a medical need". Ozempic ...

The trial tested amycretin in its injectable form, but Novo Nordisk is also separately developing the drug in pill form. Investors cheered an early trial of the pill early last year that showed weight ...

Colorado plans to start limiting insurance coverage of prescription weight-loss drugs for its roughly 40,000 state employees, a cost-cutting measure in a difficult budget year that officials say will ...

We recently published a list of 10 Best Falling Stocks to Invest in Right Now. In this article, we are going to take a look ...